These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 28719066)

  • 1. Insights into optimal basal insulin titration in type 2 diabetes: Results of a quantitative survey.
    Berard L; Bonnemaire M; Mical M; Edelman S
    Diabetes Obes Metab; 2018 Feb; 20(2):301-308. PubMed ID: 28719066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA.
    Mauricio D; Meneghini L; Seufert J; Liao L; Wang H; Tong L; Cali A; Stella P; Carita P; Khunti K
    Diabetes Obes Metab; 2017 Aug; 19(8):1155-1164. PubMed ID: 28251792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of an education programme (MEDIAS 2 BSC) of non-intensive insulin treatment regimens for people with Type 2 diabetes: a randomized, multi-centre trial.
    Hermanns N; Ehrmann D; Schall S; Maier B; Haak T; Kulzer B
    Diabet Med; 2017 Aug; 34(8):1084-1091. PubMed ID: 28257159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparable efficacy with similarly low risk of hypoglycaemia in patient- vs physician-managed basal insulin initiation and titration in insulin-naïve type 2 diabetic subjects: The Italian Titration Approach Study.
    Bonadonna RC; Giaccari A; Buzzetti R; Perseghin G; Cucinotta D; Avogaro A; Aimaretti G; Larosa M; Fanelli CG; Bolli GB
    Diabetes Metab Res Rev; 2020 Sep; 36(6):e3304. PubMed ID: 32118347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evaluation of clinical and cost outcomes associated with earlier initiation of insulin in patients with type 2 diabetes mellitus.
    Smolen HJ; Murphy DR; Gahn JC; Yu X; Curtis BH
    J Manag Care Spec Pharm; 2014 Sep; 20(9):968-84. PubMed ID: 25166296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures.
    Lingvay I; Chao J; Dalal MR; Meneghini LF
    Diabetes Technol Ther; 2017 May; 19(5):315-322. PubMed ID: 28467113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin.
    Khunti K; Nikolajsen A; Thorsted BL; Andersen M; Davies MJ; Paul SK
    Diabetes Obes Metab; 2016 Apr; 18(4):401-9. PubMed ID: 26743666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 2018 update of the American College of Physicians glycaemic management recommendations: An invitation to continued inertia?
    Morales J; Assumpcao-Morales M
    Diabetes Obes Metab; 2018 Aug; 20(8):1809-1811. PubMed ID: 29658190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initiation and Titration of Basal Insulin in Primary Care: Barriers and Practical Solutions.
    Perreault L; Vincent L; Neumiller JJ; Santos-Cavaiola T
    J Am Board Fam Med; 2019; 32(3):431-447. PubMed ID: 31068410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
    Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
    Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits of timely basal insulin control in patients with type 2 diabetes.
    Lovre D; Fonseca V
    J Diabetes Complications; 2015 Mar; 29(2):295-301. PubMed ID: 25536866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).
    Bolli GB; Riddle MC; Bergenstal RM; Ziemen M; Sestakauskas K; Goyeau H; Home PD;
    Diabetes Obes Metab; 2015 Apr; 17(4):386-94. PubMed ID: 25641260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HbA1c response after insulin initiation in patients with type 2 diabetes mellitus in real life practice: Identifying distinct subgroups.
    Sidorenkov G; van Boven JFM; Hoekstra T; Nijpels G; Hoogenberg K; Denig P
    Diabetes Obes Metab; 2018 Aug; 20(8):1957-1964. PubMed ID: 29687577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An exploratory trial of basal and prandial insulin initiation and titration for type 2 diabetes in primary care with adjunct retrospective continuous glucose monitoring: INITIATION study.
    Blackberry ID; Furler JS; Ginnivan LE; Manski-Nankervis JA; Jenkins A; Cohen N; Best JD; Young D; Liew D; Ward G; O'Neal DN
    Diabetes Res Clin Pract; 2014 Nov; 106(2):247-55. PubMed ID: 25271117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of the initial period of basal insulin titration in people with diabetes.
    Khunti K; Giorgino F; Berard L; Mauricio D; Harris SB
    Diabetes Obes Metab; 2020 May; 22(5):722-733. PubMed ID: 31865632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin regimens, diabetes knowledge, quality of life, and HbA1c in children and adolescents with type 1 diabetes.
    Keller M; Attia R; Beltrand J; Djadi-Prat J; Nguyen-Khoa T; Jay JP; Cahané M; Choleau C; Robert JJ
    Pediatr Diabetes; 2017 Aug; 18(5):340-347. PubMed ID: 27161814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness and safety of different basal insulins in a real-world setting.
    Ji L; Zhang P; Zhu D; Lu J; Guo X; Wu Y; Li X; Ji J; Jia W; Yang W; Zou D; Zhou Z; Gao Y; Garg SK; Pan C; Weng J; Paul SK;
    Diabetes Obes Metab; 2017 Aug; 19(8):1116-1126. PubMed ID: 28230322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).
    Roussel R; d'Emden MC; Fisher M; Ampudia-Blasco FJ; Stella P; Bizet F; Cali AMG; Wysham CH
    Diabetes Obes Metab; 2018 Feb; 20(2):448-452. PubMed ID: 28736942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus.
    Karl DM; Gill J; Zhou R; Riddle MC
    Diabetes Obes Metab; 2013 Jul; 15(7):622-8. PubMed ID: 23350795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial.
    Yang W; Min K; Zhou Z; Li L; Xu X; Zhu D; Venkateshwar Rao A; Murthy LS; Zhang N; Li I; Niemoeller E; Shang S
    Diabetes Obes Metab; 2018 Feb; 20(2):335-343. PubMed ID: 28742225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.